<DOC>
	<DOCNO>NCT00621179</DOCNO>
	<brief_summary>This prospective randomize trial evaluate whether one predict infertile woman endometriosis candidate vitro fertilization benefit prolong therapy GnRH agonist determination absence endometrial expression integrin , alpha v , beta 3 vitronectin . This prospective randomize trial patient undergo endometrial biopsy prior initiation ovarian stimulation vitro fertilization undergo randomization three month course depot preparation GnRH agonist leuprolide acetate depot suspension prior ovarian stimulation standard therapy . prio</brief_summary>
	<brief_title>Endometrial Markers Response Endometriosis Patients Prolonged GnRH Agonist Prior IVF</brief_title>
	<detailed_description>See summary</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Infertility Surgical diagnosis endometriosis Normal ovarian reserve test Regular menses Irregular menses Undiagnosed abnormal uterine bleeding Pregnancy Prior adverse reaction GnRH agonist Ovarian cystic solid mass &gt; 3cm mean diameter study entry Use depot preparation GnRh agonist hormonal therapy endometriosis within 6 month study entry Current hepatic , renal , hematologic psychiatric disorder</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Endometriosis , infertility , vitro fertilization</keyword>
</DOC>